Twist Bioscience Corporation updated earnings guidance for the full fiscal year 2024. For the year, Total revenue is expected to be in the range of $288 million to $293 million, growth of 18% to 20%, Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range and Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.54 USD | +1.48% | +12.84% | -14.43% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.43% | 1.82B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024